Form 4: Soleno Therapeutics Merger Completes, Shares Converted to Cash

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., with shareholders receiving $53.00 per share in cash.

Summary

• This filing reports on the completion of a merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. (through its subsidiary Sigma Merger Sub, Inc.).
• The merger was effective on May 18, 2026, with the company continuing as a subsidiary of Neocrine Biosciences, Inc.
• All outstanding shares of Soleno Therapeutics' common stock were cancelled and converted into the right to receive $53.00 in cash per share.
• Previously reported restricted stock units (RSUs) were also cancelled and converted into the right to receive $53.00 in cash per unit.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for existing shareholders, providing a clear cash return on their investment, although it marks the end of the company's independent trading.

Positives

• Shareholders received a cash payout of $53.00 per share upon the completion of the merger.
• The merger provides a definitive exit for shareholders and RSU holders.

Negatives

• The company will cease to be a publicly traded entity as it becomes a wholly owned subsidiary.
• Shareholders will no longer have direct ownership in the ongoing operations of the business.

Risks

• The filing does not explicitly detail risks associated with the merger completion itself, but the inherent risk for shareholders is the loss of future upside potential from the company's growth.

Future Outlook

The future outlook for Soleno Therapeutics as an independent entity is concluded with its acquisition. The future of the combined entity will be under Neocrine Biosciences, Inc.

Industry Context

StockSavvy.ai notes that this Form 4 filing signifies the completion of a merger, a common event in the biotechnology and pharmaceutical sectors where consolidation is driven by pipeline advancements, market access, or strategic financial maneuvers. The cash-out structure suggests a definitive acquisition rather than a stock-for-stock transaction.

Stakeholder Impact

• Shareholders: Receive $53.00 per share in cash, realizing their investment.
• RSU Holders: Receive $53.00 per RSU, realizing their equity awards.
• Employees: Their future employment status and terms will be determined by Neocrine Biosciences, Inc.
• Creditors: Their claims and agreements remain with the surviving entity, now a subsidiary of Neocrine Biosciences, Inc.

Next Steps

• The company will operate as a wholly owned subsidiary of Neocrine Biosciences, Inc.
• Shareholders and RSU holders will receive their respective cash consideration.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Acquisition, Neocrine Biosciences, SEC Form 4, Insider Trading, Restricted Stock Units, Cash Payout